Neurocysticercosis: Neurology and neurobiology

Neglected Tropical Diseases and Conditions of the Nervous System

Volumn , Issue , 2014, Pages 127-146

  Carpio, Arturo ^a,b,c   Fleury, Agnès ^d,e  

^a UNIVERSIDAD DE CUENCA   (Ecuador)

^b Vagelos College of Physicians and Surgeons   (United States)

^c F Proano y D Cordova (esquina)   (Ecuador)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Albendazole; Epilepsy; Imaging; Parasitic infection; Praziquantel; Seizures; Taenia solium; Taeniasis cysticercosis

Indexed keywords

EID: 84948146980     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-8100-3_7     Document Type: Chapter

References (112)

1. Abba K, (1993) Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep 42:1-38.
2. Abba K, Ramaratnam S, Ranganathan LN (2010) Antihelmintics for people with neurocysticerco- sis. Cochrane Database Syst Rev 3, CD000215.
3. Adalid-Peralta L, Fleury A, Garrfa-Ibarra TM, Hernandez M, Parkhouse M, Crispm JC, Voltaire- Proano J, Cardenas G, Fragoso G, Sciutto E (2012) Human neurocysticercosis: in vivo expan- sion of peripheral regulatory T cells and their recruitment in the central nervous system. J Parasitol 98:142-148.
4. Agapejev S, Pouza AF, Bazan R, Faleiros AT (2007) Clinical and evolutive aspects of hydrocepha- lus in neurocysticercosis. Arq Neuropsiquiatr 65:674-680.
5. Aguilar-Daz H, Bobes RJ, Carrero JC et al (2006) The genome project of Taenia solium. Parasitol Int 55(Suppl):S127-S130.
6. Allan JC, Velasquez-Tohom M, Fletes C, Torres-Alvarez R, Lopez-Virula G, Yurrita P, Soto de Alfaro H, Rivera A, Garcia-Noval J (1997) Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs. Trans R Soc Trop Med Hyg 91:595-598.
7. Alsina GA, Johnson JP, McBride DQ, Rhoten PRL, Mehringer CM, Stokes JK (2002) Spinal neurocysticercosis. Neurosurg Focus 12:1-7.
8. Aluja A, Escobar A, Escobedo F, Flisser A et al (1987) Cisticercosis: Una recopilacion actualizada de los conocimientos basicos para el manejo y control de la cisticercosis causada por Taenia solium.
9. Fondo de Cultura Economica, Biblioteca de la salud, Mexico Alvarez JI, Colegial CH, Castano CA et al (2002) The human nervous tissue in proximity to granulomatous lesions induced by Taenia solium metacestodes displays an active response. J Neuroimmunol 127:139-144.
10. Antoniuk SA, Bruck I, Dos Santos LH et al (2001) Seizures associated with calcifications and edema in neurocysticercosis. Pediatr Neurol 25:309-311.
11. Bhattarai R, Budke CM, Carabin H et al (2012) Estimating the non-monetary burden of neurocys- ticercosis in Mexico. PLoS Negl Trop Dis 6:e1521.
12. Blocher J, Schmutzhard E, Wilkins PP, Gupton PN, Schaffert M, Auer H, Gotwald T, Matuja W, Winkler AS (2011) A cross-sectional study of people with epilepsy and neurocysticercosis in Tanzania: clinical characteristics and diagnostic approaches. PLoS Negl Trop Dis 5:e1185.
13. Bobes RJ, Fragoso G, Reyes-Montes M del R, Duarte-Escalante E, Vega R, de Aluja AS, Zuniga G, Morales J, Larralde C, Sciutto E (2010) Genetic diversity of Taenia solium cysticerci from naturally infected pigs of central Mexico. Vet Parasitol 168:130-135.
14. Braga F, Rocha AJ, Gomes HR, Filho GH, Silva CJ, Fonseca RB (2004) Noninvasive MR cister- nography with fluid-attenuated inversion recovery and 100% Supplemental O2 in the evalua- tion of neurocysticercosis. AJNR Am J Neuroradiol 25:295-297.
15. Brandt JR, Geerts S, De Deken R et al (1992) A monoclonal antibody-based ELISA for the detection of circulating excretory-secretory antigens in Taenia saginata cysticercosis. Int J Parasitol 22:471-477.
16. Bueno EC, Vaz AJ, Machado LD, Livramento JA (2000) Neurocysticercosis: detection of IgG, IgA and IgE antibodies in cerebrospinal fluid, serum and saliva samples by ELISA with Taenia solium and Taenia crassiceps antigens. Arq Neuropsiquiatr 58:18-24.
17. Carabin H, Ndimubanzi PC, Budke CM, Nguyen H, Qian Y, Cowan LD, Stoner JA, Rainwater E, Dickey M (2011) Clinical manifestations associated with eurocysticercosis: a systematic review. PLoS Negl Trop Dis 5:e1152.
18. Cardenas G, Carrillo-Meza R, Jung H et al (2010a) Subarachnoidal neurocysticercosis non- responsive to cysticidal drugs: a case series. BMC Neurol 10:16.
19. Cardenas G, Jung H, Rfos C, Fleury A, Soto-Hernandez JL (2010b) Severe cysticercal meningitis: clinical and imaging characteristics. Am J Trop Med Hyg 82:121-125.
20. Carpio A, Fleury A. Hauser WA (2013) Neurocysticercosis: five new things. Neurol Clin Pract 3:118-125.
21. Carpio A, Hauser W (2002) Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 59:1730-1734.
22. Carpio A, Hauser WA (2009) Epilepsy in the developing world. Curr Neurol Neurosci Rep 9:319-326.
23. Carpio A, Placencia M, Santillan F, Escobar A (1994) A proposal for a classification of neurocys- ticercosis. Can J Neurosci 21:43-47.
24. Carpio A, Escobar A, Hauser WA (1998) Epilepsy and cysticercosis: a critical review. Epilepsia 39:1025-1040.
25. Carpio A, Kelvin E, Bagiella E, Leslie D, Leon P, Andrews H, Hauser WA (2008) Effects of albendazole treatment on neurocysticercosis: a randomized controlled trial. J Neurol Neurosurg Psychiatry 79:1050-1055.
26. Chavarria A, Roger B, Fragoso G, Tapia G, Fleury A, Dumas M, Dessein A, Larralde C, Sciutto E (2003) TH2 profile in asymptomatic Taenia solium human neurocysticercosis. Microbes Infect 5:1109-1115.
27. Chavarria A, Fleury A, Gartfa E, Marquez C, Fragoso G, Sciutto E (2005) Relationship between the clinical heterogeneity of neurocysticercosis and the immune-inflammatory profiles. Clin Immunol 116:271-278.
28. Chavarria A, Fleury A, Bobes RJ, Morales J, Fragoso G, Sciutto E (2006) A depressed peripheral cel- lular immune response is related to symptomatic neurocysticercosis. Microbes Infect 8:1082-1089.
29. Croker C, Redelings M, Reporter R, Sorvillo F, Mascola L, Wilkins P (2012) The impact of neu- rocysticercosis in California: a review of hospitalized cases. PLoS Negl Trop Dis 6:e1480.
30. Cukiert A, Puglia P, Scapolan HB, Vilela MM, Marino Junior R (1994) Congruence of the topog- raphy of intracranial calcifications and epileptic foci. Arq Neuropsiquiatr 52:289-294.
31. Das K, Mondal GP, Banerjee M, Mukherjee BB, Singh OP (2007) Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J Clin Neurosci 14:1172-1177.
32. De Aluja A, Morales Soto J, Sciutto E (2012) A programme to control taeniosis-cysticercosis (Taenia solium) in Mexico. In: Rodriguez-Morales A (ed) Current topics in tropical medicine. InTech, New York, available from: http://www.intechopen.com/books/current-topics-in- tropical-medicine/a-program-to-control-taeniosis-cysticercosis-taenia-solium-in-mexico.
33. De Souza A, Thennarasu K, Yeshraj G, Kovoor JM, Nalini A (2009) Randomized controlled trial of albendazole in new onset epilepsy and MRI confirmed solitary cerebral cysticercal lesion: effect on long-term seizure outcome. J Neurol Sci 276:108-114.
34. Del Brutto OH, Rajshekhar V, White AC Jr et al (2001) Proposed diagnostic criteria for neurocys- ticercosis. Neurology 57:177-183.
35. Del Brutto OH, Roos KL, Coffey CS, Garcia HH (2006) Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 45:43-51.
36. Diazgranados-Sanchez JA, Barrios-Arrazola G, Costa JL, Burbano-Pabon J, Pinzon-Bedoya J (2008) Ivermectin as a therapeutic alternative in neurocysticercosis that is resistant to conven- tional pharmacological treatment. Rev Neurol 46:671-674.
37. Dumas JL, Visy JM, Belin C, Gaston A, Goldlust D, Dumas M (1997) Parenchymal neurocysticer- cosis: follow-up and staging by MRI. Neuroradiology 39:12-18.
38. Escobar A (1983) The pathology of neurocysticercosis. In: Palacios E, Rodriguez-Carbajal J, Taveras JM (eds) Cysticercosis of central nervous system.
39. Charles C Thomas, Springfield Estanol B, Corona T, Abad P (1986) A prognostic classification of cerebral cysticercosis: therapeutic implications. J Neurol Neurosurg Psychiatry 49:1131-1134.
40. Ferreira LS, Zanardi VA, Scotoni AE, Li LM, Guerreiro MM (2001) Childhood epilepsy due to neurocysticercosis: a comparative study. Epilepsia 42:1438-1444.
41. Ferreira LS, Li LM, Zanardi VA, Guerreiro MM (2002) Number and viability of parasite influence seizure frequency in children with neurocysticercosis. Arq Neuropsiquiatr 60:909-911.
42. Fleury A, Morales J, Bobes RJ, Dumas M, Yanez O, Pina J, Carrillo-Mezo R, Martmez JJ, Fragoso G, Dessein A, Larralde C, Sciutto E (2006) An epidemiological study of familial neurocysticer- cosis in an endemic Mexican community. Trans R Soc Trop Med Hyg 100:551-558.
43. Fleury A, Hernandez M, Avila M, Cardenas G, Bobes RJ, Huerta M, Fragoso G, Uribe-Campero L, Harrison LJ, Parkhouse RM, Sciutto E (2007) Detection of HP10 antigen in serum for diag- nosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis. J Neurol Neurosurg Psychiatry 78:970-974.
44. Fleury A, Escobar A, Fragoso G, Sciutto E, Larralde C (2010) Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Trans R Soc Trop Med Hyg 104:243-250.
45. Fleury A, Carrillo-Mezo R, Flisser A, Sciutto E, Corona T (2011) Subarachnoid basal neurocysticer- cosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 9: 123-133.
46. Flisser A, Espinoza B, Tovar A, Plancarte A, Correa D (1986) Host-parasite relationship in cysti- cercosis: immunologic study in different compartments of the host. Vet Parasitol 20:95-102.
47. Forlenza OV, Filho AH, Nobrega JP, dos Ramos Machado L, de Barros NG, de Camargo CH, da Silva MF (1997) Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry 62: 612-616.
48. Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, Herrera G, Evans CA, Gonzalez AE; Cysticercosis Working Group in Peru (2004) A trial of antiparasitic treat- ment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 350:249-258.
49. Garcia-Dominguez C, Correa D, Rabiela MT, Flisser A (1991) Praziquantel treatment of muscle Taenia solium cysticercosis. 4. Reversible in vitro effect. Parasitol Res 77:691-696.
50. Goel RK, Ahmad FU, Vellimana AK, Suri A, Chandra PS, Kumar R, Sharma BS, Mahapatra AK (2008) Endoscopic management of intraventricular neurocysticercosis. J Clin Neurosci 15:1096-1101.
51. Goel D, Mittal M, Bansal KK, Singhal A (2010) Natural history of solitary cerebral cysticercosis cases after albendazole therapy: a longitudinal follow-up study from India. Acta Neurol Scand 121:204-208.
52. Gonzalez AE, Gavidia C, Falcon N, Bernal T, Verastegui M, Garcia HH, Gilman RH, Tsang VC; Cysticercosis Working Group in Peru (2001) Protection of pigs with cysticercosis from further infections after treatment with oxfendazole. Am J Trop Med Hyg 65:15-18.
53. Goodman K, Ballagh SA, Carpio A (1999) Case control study of seropositivity for cysticercosis in Cuenca, Ecuador. Am J Trop Med Hyg 60:70-74.
54. Huerta M, de Aluja AS, Fragoso G, Toledo A, Villalobos N, Hernandez M, Gevorkian G, Acero G, Daz A, Alvarez I, Avila R, Beltran C, Garcia G, Martinez JJ, Larralde C, Sciutto E (2001) Synthetic peptide vaccine against Taenia solium pig cysticercosis: successful vaccination in a controlled field trial in rural Mexico. Vaccine 20:262-266.
55. Jain S, Padma MV, Kanga U, Mehra NK, Puri A, Maheshwari MC (1999) Family studies and human leukocyte antigen class II typing in Indian probands with seizures in association with single small enhancing computed tomography lesions. Epilepsia 40:232-238.
56. Jung-Cook H (2012) Pharmacokinetic variability of antihelmintics: implications for the treatment of neurocysticercosis. Expert Rev Clin Pharmacol 5:21-30.
57. Kelvin EA, Carpio A, Bagiella E, Leslie D, Leon P, Andrews H, Hauser WA; Ecuadorian Neurocysticercosis Group (2009a) The association of host age and gender with inflammation around neurocysticercosis cysts. Ann Trop Med Parasitol 103:487-499.
58. Kelvin EA, Carpio A, Hesdorffer DC, Bagiella E, Leslie D, Leon P, Andrews H, Hauser WA; Ecuadorian Neurocysticercosis Group (2009b) Investigation of familial aggregation of seizures in neurocysticercosis patients. Epilepsy Res 84:67-71.
59. Kelvin EA, Carpio A, Bagiella E, Leslie D, Leon P, Andrews H, Hauser WA; Ecuadorian Neurocysticercosis Group (2011) Seizure in people with newly diagnosed active or transitional neurocysticercosis. Seizure 20:119-125.
60. Kioumehr F, Dadsetan MR, Feldman N, Mathison G, Moosavi H, Rooholamini SA, Verma RC (1995) Postcontrast MRI of cranial meninges: leptomeningitis versus pachymeningitis. J Comput Assist Tomogr 19:713-720.
61. Kowacs PA, Rogacheski E, Muzzio J, Werneck LC (2006) The role of the irritative zone and of the number and distribution of calcifications in the severity of epilepsy associated with intracranial calcifications. Arq Neuropsiquiatr 64:905-911.
62. Lacey E (1990) Mode of action of benzimidazoles. Parasitol Today 6:112-115.
63. Laclette JP, Ornelas Y, Merchant MT, Willms K (1982) Ultrastructure of the surrounding enve- lopes of Taenia solium eggs. In: Flisser A, Willms K, Laclette JP et al (eds) Cysticercosis: present state of knowledge and perspectives. Academic, New York.
64. Laclette JP, Shoemaker CB, Richter D, Arcos L, Pante N, Cohen C, Bing D, Nicholson-Weller A (1992) Paramyosin inhibits complement C1. J Immunol 148:124-128.
65. Leite JP, Terra-Bustamante VC, Fernandes RM, Santos AC, Chimelli L, Sakamoto AC, Assirati JA, Takayanagui OM (2000) Calcified neurocysticercotic lesions and postsurgery seizure con- trol in temporal lobe epilepsy. Neurology 55:1485-1491.
66. Loureiro das Chagas MG, D'Oliveira A Jr, Tavares-Neto J (2003) Clinical aspects of neurocysti- cercosis at semi-desert region of the Brazilian northeast. Arq Neuropsiquiatr 61:398-402.
67. Lucato LT, Guedes MS, Sato JR, Bacheschi LA, Machado LR, Leite CC (2007) The role of conven- tional MR imaging sequences in the evaluation of neurocysticercosis: impact on characteriza- tion of the scolex and lesion burden. AJNR Am J Neuroradiol 28:1501-1504.
68. Machado LR (2010) The diagnosis of neurocysticercosis: a closed question? Arq Neuropsiquiatr 68:1-2.
69. Manreza ML (2000) Epilepsia e neurocisticerose. In: Guerreiro CAM, Guerreiro MM, Cendes F, Lopes-Cendes I (eds) Epilepsia. Lemos Editorial, Sao.
70. Paulo Maravilla P, Souza V, Valera A et al (2003) Detection of genetic variation in Taenia solium. J Parasitol 89:1250-1254.
71. Maravilla P, Gonzalez-Guzman R, Zuniga G, Peniche A, Dominguez-Alpizar JL, Reyes-Montes R, Flisser A (2008) Genetic polymorphism in Taenia solium cysticerci recovered from experi- mental infections in pigs. Infect Genet Evol 8:213-216.
72. Michelet L, Fleury A, Sciutto E, Kendjo E, Fragoso G, Paris L, Bouteille B (2011) Human neuro- cysticercosis: comparison of different diagnostic tests in cerebrospinal fluid. J Clin Microbiol 49:195-200.
73. Mont'Alverne Filho FE, Machado Ldos R, Lucato LT, Leite CC (2011) The role of 3D volu- metric MR sequences in diagnosing intraventricular neurocysticercosis: preliminary results. Arq Neuropsiquiatr 69:74-78.
74. Murthy JM, Yangala R (1999) Acute symptomatic seizures - incidence and etiological spectrum: a hospital-based study from South India. Seizure 8:162-165.
75. Nash TE, Pretell EJ, Lescano AG, Bustos JA, Gilman RH, Gonzalez AE, Garcia HH; Cysticercosis Working Group in Peru (2008) Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol 7:1099-1105.
76. Ndimubanzi PC, Carabin H, Budke CM, Nguyen H, Qian YJ, Rainwater E, Dickey M, Reynolds S, Stoner JA (2010) A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis 4:e870.
77. Ngowi HA, Carabin H, Kassuku AA, Mlozi MR, Mlangwa JE, Willingham AL (2008) A health-education intervention trial to reduce porcine cysticercosis in Mbulu District, Tanzania. Prev Vet Med 85:52-67.
78. Pal DK, Carpio A, Sander JWAS (2000) Neurocysticercosis and epilepsy. J Neurol Neurosurg Psychiatry 68:137-143.
79. Patel R, Jha S, Yadav RK (2006) Pleomorphism of the clinical manifestations of neurocysticercosis. Trans R Soc Trop Med Hyg 100:134-141.
80. Proano JV, Torres-Corzo J, Rodnguez-Della Vecchia R, Guizar-Sahagun G, Rangel-Castilla L (2009) Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery. Childs Nerv Syst 25:1467-1475.
81. Proano-Narvaez JV, Meza-Lucas A, Mata-Ruiz O, Gartfa-Jeronimo RC, Correa D (2002) Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. J Clin Microbiol 40:2115-2118.
82. Rabiela MT, Rivas A, Flisser A (1989) Morphological types of Taenia solium cysticerci. Parasitol Today 5:357-359.
83. Ramos-Kuri M, Montoya RM, Padilla A, Govezensky T, Daz ML, Sciutto E, Sotelo J, Larralde C (2002) Immunodiagnosis of neurocysticercosis. Disappointing performance of serology (enzyme-linked immunosorbent assay) in an unbiased sample of neurological patients. Arch Neurol 49:633-636.
84. Rathore C, Thomas B, Kesavadas C, Radhakrishnan K (2012) Calcified neurocysticercosis lesions and hippocampal sclerosis: potential dual pathology? Epilepsia 53:e60-62. doi: 10.1111/j. 1528-1167.2011.03386.x.
85. Robles C, Chavarria M (1979) Presentacion de un caso clinico de cisticercosis cerebral tratado medicamente con un nuevo farmaco: Praziquantel. Salud Pub Mex XXI:603-618.
86. Rodrigues CL, de Andrade DC, Livramento JA, Machado LR, Abraham R, Massaroppe L, Lucato LT, Caramelli P (2012) Spectrum of cognitive impairment in neurocysticercosis: differences according to disease phase. Neurology 78:861-866.
87. Rosenfeld EA, Byrd SE, Shulman ST (1996) Neurocysticercosis among children in Chicago. Clin Infect Dis 23:262-268.
88. Ruiz-Garcia M, Gonzalez-Astiazaran A, Rueda-Franco F (1997) Neurocysticercosis in children. Clinical experience in 122 patients. Childs Nerv Syst 13:608-612.
89. Saenz B, Rmz-Garcia M, Jimenez E, Hernandez-Aguilar J, Suastegui R, Larralde C, Sciutto E, Fleury A (2006) Neurocysticercosis: Clinical. Radiologic, and inflammatory differences between children and adults. Pediatr Infect Dis J 25:801-803.
90. Sakamoto AC et al (1999) Cysticercosis and epilepsy. In: Kotagal P, Luders HO (eds) The epilepsies: etiologies and prevention. Academic, San Diego.
91. Sarti E, Schantz PM, Avila G, Ambrosio J, Medina-Santillan R, Flisser A (2000) Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study. Trans R Soc Trop Med Hyg 94:85-89.
92. Sciutto E, Rosas G, Hernandez M, Morales J, Cruz-Revilla C, Toledo A, Manoutcharian K, Gevorkian G, Blancas A, Acero G, Hernandez B, Cervantes J, Bobes RJ, Goldbaum FA, Huerta M, Diaz-Orea A, Fleury A, de Aluja AS, Cabrera-Ponce JL, Herrera-Estrella L, Fragoso G, Larralde C (2007) Improvement of the synthetic tri-peptide vaccine (S3Pvac) against porcine Taenia solium cysticercosis in search of a more effective, inexpensive and manageable vaccine. Vaccine 25:1368-1378.
93. Sharma P, Garg RK, Verma R, Singh MK, Shukla R (2011) Risk of seizure recurrence in patients of new-onset partial seizure having a solitary cysticercus granuloma of brain or normal neuro- imaging. J Neurol Sci 301:21-26.
94. Sikasunge CS, Johansen MV, Willingham AL, Leifsson PS, Phiri IK (2008) Taenia solium porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal anti- gens after treatment with oxfendazole. Vet Parasitol 158:57-66.
95. Singh G (1997) Neurocysticercosis in South-Central America and the Indian subcontinent. A com- parative evaluation. Arq Neuropsiquiatr 55:349-356.
96. Singh G, Kaushal V, Ram S, Kaushal RK, Dhanuka AK, Khurana S (1999) Cysticercus immunoblot assay in patients with single, small enhancing lesions and multilesional neurocysticercosis. J Assoc Physicians India 47:476-479.
97. Singh G, Rajshekhar V, Murthy JM, Prabhakar S, Modi M, Khandelwal N, Garcia HH (2010) A diag- nostic and therapeutic scheme for a solitary cysticercus granuloma. Neurology 75:2236-2245.
98. Singhi P, Ray M, Singhi S, Khandelwal N (2000) Clinical spectrum of 500 children with neurocys- ticercosis and response to albendazole therapy. J Child Neurol 15:207-213.
99. Sotelo J, Marin C (1987) Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg 66:686-689.
100. Sotelo J, Guerrero J, Rubio F (1988) A new classification based on active and inactive forms. Arch Intern Med 148:442-445.
101. Takayanagui OM, Odashima NS, Bonato PS, Lima JE, Lanchote VL (2011) Medical management of neurocysticercosis. Expert Opin Pharmacother 12:2845-2856.
102. Terra-Bustamante VC, Coimbra ER, Rezek KO, Escorsi-Rosset SR, Guarnieri R, Dalmagro CL, Inuzuka LM, Bianchin MM, Wichert-Ana L, Alexandre V, Takayanagui OM, Araujo D, dos Santos AC, Carlotti CG, Walz R, Markowitsch HJ, Sakamoto AC (2005) Cognitive performance of patients with mesial temporal lobe epilepsy and incidental calcified neurocysticerco- sis. J Neurol Neurosurg Psychiatry 76:1080-1083.
103. Thussu A, Chattopadhyay A, Sawhney IM, Khandelwal N (2008) Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. J Neurol Neurosurg Psychiatry 79:272-275.
104. Torres-Corzo JG, Tapia-Perez JH, Vecchia RR, Chalita-Williams JC, Sanchez-Aguilar M, Sanchez- Rodnguez JJ (2010) Endoscopic management of hydrocephalus due to neurocysticercosis. Clin Neurol Neurosurg 112:11-16.
105. Tsang VC, Brand JA, Boyer AE (1989) An enzyme-linked immunoelectrotransfer blot assay and glycoproteins antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 174: 1007-1009.
106. Vega R, Pinero D, Ramanankandrasana B, Dumas M, Bouteille B, Fleury A, Sciutto E, Larralde C, Fragoso G (2003) Population genetic structure of Taenia solium from Madagascar and Mexico: impli- cations for clinical profile diversity and immunological technology. Int J Parasitol 33:1479-1485.
107. Velasco TR, Zanello PA, Dalmagro CL, Araujo D Jr, Santos AC, Bianchin MM, Alexandre V Jr, Walz R, Assirati JA, Carlotti CG Jr, Takayanagui OM, Sakamoto AC, Leite JP (2006) Calcified cysticercotic lesions and intractable epilepsy: a cross sectional study of 512 patients. J Neurol Neurosurg Psychiatry 77:485-488.
108. WHO (2007) Global plan to combat neglected tropical diseases 2008-2015. World Health Organization, Geneva.
109. Wilson M, Gryan R, Fried J, Ware D, Schantz P, Pilcher JB, Tsang VCW (1991) Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticerco- sis. J Infect Dis 164:1007-1009.
110. Winkler AS, Blocher J, Auer H, Gotwald T, Matuja W, Schmutzhard E (2008) Anticysticercal and antitoxocaral antibodies in people with epilepsy in rural Tanzania. Trans R Soc Trop Med Hyg 102:1032-1038.
111. Xiao ZX, Zhao CY, Liu LP (1986) Albendazole treatment in cerebral cysticercosis. Chin J Int Med 25:100-102.
112. Zee CS, Go JL, Kim PE, DiGiorgio CM (2000) Imaging of neurocysticercosis. Neuroimaging Clin N Am 10:391-407.